BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11074745)

  • 1. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators.
    Stewart RA; Sharples KJ; North FM; Menkes DB; Baker J; Simes J
    Arch Intern Med; 2000 Nov; 160(20):3144-52. PubMed ID: 11074745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia.
    Morris R; Robinson G; Tilyard M; Gurr E
    N Z Med J; 1996 Aug; 109(1028):319-22. PubMed ID: 8816723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-masked comparison of the quality of life of hypercholesterolemic men treated with simvastatin or pravastatin. International Quality of Life Multicenter Group.
    Seed M; Weir MR
    Clin Ther; 1999 Oct; 21(10):1758-70. PubMed ID: 10566571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pravastatin in patients with cardiac risk factors. Effects of pravastatin in patients with total serum cholesterol concentrations of 200 to 300 mg/dl (5.2 to 7.8 mmol/l) and two additional atherosclerosis risk factors. Pravastatin Multinational Study Group for Cardiac Risk Patients].
    Fortschr Med; 1994 Feb; 112(5):57-64. PubMed ID: 8163252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
    Lewis JH; Mortensen ME; Zweig S; Fusco MJ; Medoff JR; Belder R;
    Hepatology; 2007 Nov; 46(5):1453-63. PubMed ID: 17668878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects.
    Chan P; Tomlinson B; Lee CB; Pan WH; Lee YS
    Hypertension; 1996 Oct; 28(4):647-51. PubMed ID: 8843892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of the month. The LIPID study: "long-term intervention with pravastatin in ischaemic disease"].
    Scheen AJ
    Rev Med Liege; 1999 Jan; 54(1):2-3. PubMed ID: 10081301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events.
    Pfeffer MA; Sacks FM; Moyé LA; East C; Goldman S; Nash DT; Rouleau JR; Rouleau JL; Sussex BA; Theroux P; Vanden Belt RJ; Braunwald E
    J Am Coll Cardiol; 1999 Jan; 33(1):125-30. PubMed ID: 9935018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring cholesterol levels: measurement error or true change?
    Glasziou PP; Irwig L; Heritier S; Simes RJ; Tonkin A;
    Ann Intern Med; 2008 May; 148(9):656-61. PubMed ID: 18458278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico).
    Ital Heart J; 2000 Dec; 1(12):810-20. PubMed ID: 11302109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients.
    Am J Cardiol; 1993 Nov; 72(14):1031-7. PubMed ID: 8213583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group.
    Cobbaert C; Jukema JW; Zwinderman AH; Withagen AJ; Lindemans J; Bruschke AV
    J Am Coll Cardiol; 1997 Nov; 30(6):1491-9. PubMed ID: 9362407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults.
    Carlsson CM; Papcke-Benson K; Carnes M; McBride PE; Stein JH
    Drugs Aging; 2002; 19(10):793-805. PubMed ID: 12390056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
    Plehn JF; Davis BR; Sacks FM; Rouleau JL; Pfeffer MA; Bernstein V; Cuddy TE; Moyé LA; Piller LB; Rutherford J; Simpson LM; Braunwald E
    Circulation; 1999 Jan; 99(2):216-23. PubMed ID: 9892586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group.
    J Atheroscler Thromb; 1996; 3(2):95-104. PubMed ID: 9226461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.
    Lewis SJ; Moye LA; Sacks FM; Johnstone DE; Timmis G; Mitchell J; Limacher M; Kell S; Glasser SP; Grant J; Davis BR; Pfeffer MA; Braunwald E
    Ann Intern Med; 1998 Nov; 129(9):681-9. PubMed ID: 9841599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia.
    Raskin P; Ganda OP; Schwartz S; Willard D; Rosenstock J; Lodewick PA; Cressman MD; Phillipson B; Weiner B; McGovern ME
    Am J Med; 1995 Oct; 99(4):362-9. PubMed ID: 7573090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.